Clinical Trial

The DolPHIN 2 Clinical Trial is designed to yield high-quality evidence on the efficacy and safety of dolutegravir in late presenting pregnant women, to allow definitive recommendations for use of dolutegravir to reduce vertical transmission in this high-risk scenario.  

The study commenced recruitment in January 2018 and recruited over 268 late presenting pregnant women living with HIV who were randomised 1:1 to DTG- or EFV-containing cART. The trial primary outcome analysis was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in March 2019. 

Women living with HIV starting dolutegravir (DTG)-based ART after presenting in late pregnancy achieved more rapid virological suppression before delivery than those who started with an efavirenz (EFV)-based regimen.

You can learn more about the trial results by accessing the CROI presentation slides and reading our policy brief. Learn more about the day-to-day reality of the trial by following the links to the right and below.